BofA raised the firm’s price target on Merus to $61 from $52 and keeps a Buy rating on the shares after the company reported 60% objective response rate, or ORR, in 10 evaluable patients from the cohort evaluating petosemtamab in combination with pembrolizumab in first-line head and neck squamous cell carcinoma, or HNSCC. Given this “positive” interim data, the firm increased its view on the odds of success for petosemtamab in this indication to 50% from 30% previously.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
- Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
- Merus granted BTD by the FDA for petosemtamab
- Merus reports Q1 EPS (59c), consensus (81c)
- Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update